Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Four different classes of HDACs have been identified in humans so far. Classes I, II and IV are zinc-dependent amidohydrolases, while III is a family of phylogenetically conserved NAD-dependent protein deacetylases/ADP-ribosyltransferase with a welldefined role in modifying chromatin conformation and altering the accessibility of the damaged sites of DNA for repair enzymes. Sirtuins are histone deacetylases (HDACs) of class III that cleave off acetyl groups from acetyl-lysine residues in histones and non-histone proteins. As sirtuins are involved in many physiological and pathological processes, their activity has been associated with different human diseases, including cancer. Especially two sirtuin members, SIRT1 and SIRT2, have been found to antagonize p53-dependent transcriptional activation and apoptosis in response to DNA damage by catalyzing p53 deacetylation. The findings that SIRT1 levels are increased in a number of tumors highlight the oncogenic role of sirtuins, in particular, in the down-modulation of p53 oncosuppressor activity. Along this lane, cancers carrying wild-type (wt) p53 protein are known to deregulate its activity by other mechanisms. Therefore, inhibition of SIRT1 and SIRT2, aimed at restoring wt-p53 transcriptional activity in tumors that retain the ability to express normal p53, might represent a valid therapeutic cancer approach specially when combined with standard therapies. This review will be focused on sirtuin inhibitors, with a specific attention on inhibitors of SIRT1 and SIRT2. Among them, nicotinamide and its analogs, sirtinol, A3 and M15, splitomicin, HR73 and derivatives, cambinol and derivatives, EX 527, kinase inhibitors, suramin, 4-dihydropyridine derivatives, tenovins, TRIPOS 360702, AC 93253, 3-arylideneindolinones, CSC8 and CSC13 will also be described.

Keywords: Antitumoral activity; SIRT1; SIRT2; inhibitors; sirtuin

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986712804143303

Publication date: December 1, 2012

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more